Edition:
India

Catalyst Biosciences Inc (CBIO.OQ)

CBIO.OQ on NASDAQ Stock Exchange Capital Market

19.49USD
19 Jan 2018
Change (% chg)

$0.86 (+4.62%)
Prev Close
$18.63
Open
$18.82
Day's High
$19.49
Day's Low
$18.75
Volume
60,965
Avg. Vol
58,659
52-wk High
$19.49
52-wk Low
$3.13

Select another date:

Thu, Jan 4 2018

BRIEF-Catalyst Biosciences Initiates Phase 2/3 Trial Of Marzeptacog Alfa (Activated)

* CATALYST BIOSCIENCES INITIATES PHASE 2/3 TRIAL OF MARZEPTACOG ALFA (ACTIVATED) FOR PROPHYLAXIS IN HEMOPHILIA A OR B WITH INHIBITORS

BRIEF-Nexthera Capital Reports 5.4 Pct Passive Stake In Catalyst Biosciences

* NEXTHERA CAPITAL REPORTS A 5.4 PERCENT PASSIVE STAKE IN CATALYST BIOSCIENCES AS OF DEC 20 - SEC FILING Source text : (http://bit.ly/2l9OsLV) Further company coverage:

BRIEF-Catalyst Biosciences Announces Pricing Of Public Offering Of Common Stock

* CATALYST BIOSCIENCES ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Catalyst Biosciences Announces Proposed Public Offering Of Common Stock

* CATALYST BIOSCIENCES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Catalyst Biosciences Appoints Edward Williams To Its Board

* CATALYST BIOSCIENCES ANNOUNCES APPOINTMENT OF EDWARD WILLIAMS TO ITS BOARD OF DIRECTORS

BRIEF-Catalyst biosciences Q3 loss per share $1.34

* Catalyst Biosciences reports third quarter 2017 operating & financial results and provides corporate update

BRIEF-Catalyst Biosciences and Mosaic Biosciences enter into strategic collaboration

* Catalyst Biosciences and Mosaic Biosciences enter into strategic collaboration to develop intravitreal anti-complement factor 3 (c3) products for the treatment of dry amd and other retinal diseases

BRIEF-Catalyst Biosciences Inc - ‍companies plan to have interim, top-line results by end of 2017

* Catalyst Biosciences granted FDA orphan drug designation for subcutaneous recombinant human Factor IX variant for treatment of hemophilia B

BRIEF-Catalyst Biosciences announces successful completion of first subcutaneous dosing cohort in ongoing hemophilia B clinical trial

* Catalyst Biosciences announces successful completion of first subcutaneous dosing cohort in ongoing hemophilia B clinical trial

BRIEF-Catalyst Biosciences Inc announces issuance of Asia patents covering Factor IX Hemophilia Program

* Catalyst Biosciences Inc - announces issuance of Asia patents covering factor IX Hemophilia Program Source text for Eikon: Further company coverage:

Select another date: